Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

A network pharmacology-based study on the hepatoprotective effect and hepatotoxic effect of Chinese medicines

World Congress on Immuno Oncology & Clinical Pharmacy
April 18-19, 2019 | Paris, France

Yibin Feng

School of Chinese Medicine-Li Ka Shing Faculty of Medicine, The Chinese University of Hong Kong, PR of China

Keynote: Arch Cancer Res

Abstract:

Drug discovery from Chinese Medicines, such as artemisinin, arsenic trioxide, ursodeoxycholic acid etc. have big impact on modern clinical setting. Indeed, traditional wisdom of Chinese medicines has contributed to modern drug discovery in the above cases. However, different from single pure compound used in western drugs, Traditional Chinese Medicines in real world are multiple components because they are consist of plants, animal parts and minerals. The chemical profiles and pharmacological features of Chinese Medicines are obviously different from pure chemical compound. In the past decades, therapeutic effects and mechanisms of Chinese medicines and their formulae have been intensively studied. Facing multiple components, how to get whole picture and scientific evidence of Chinese Medicines is a challenge. Network-pharmacology should be powerful approaches. The presentation will show some cases of our original research hepatoprotective effect and hepatotoxic effect of Chinese Medicines by using network-pharmacology and discuss the issues related to the research.

Biography :

Yibin Feng is currently an Associate Professor cum Associate Director (education) in School of Chinese Medicine, The University of Hong Kong. So far, he has secured a lot of grants and has published over 400 publications to explore scientific evidence for Chinese herbal medicines in prevention and treatment of cancer and metabolic diseases. He was listed as one of HKU Scholars in the Top 1% by 2018 Essential Science Indicators. His passion and achievements attract excellent students and now he has six PhD students and four Postdoc Fellows in his research team. He played a leading role in professional and international academic communities, serving as the Chairperson for several international conferences and having been invited by lots of international conferences as Keynote or Plenary Speaker. He has served as Advisor/ Expert Committee Member for government agencies, professional bodies and WHO. He also served as an Editor and Reviewer for numbers of international journals.

E-mail: yfeng@hku.hk